The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Abstract
Purpose: To assess the efficacy and tolerability of bortezomib with or without dexamethasone and to define prognostic factors for patients with primary systemic light chain (AL) amyloidosis treated with bortezomib or both. Patients and Methods: Ninety-four patients from three centers were analyzed: 19% received the combination as first-line treatment, 81% had a median of two previous therapies, and 69% had refractory disease, while most patients had symptomatic heart involvement or elevated serum N-terminal pro-brain natriuretic peptide (NT-proBNP). Results: A hematologic response was achieved in 71% within a median of 52 days, including 25% complete responses (CRs). Previously untreated patients had a 47% CR rate. Age 65 years or younger (P = .043) and twice weekly administration of bortezomib (P = .041) were associated with higher response rates. A cardiac response was documented in 29% of patients, in most as sustained improvement of functional class and less often as a decrease in wall thickness. Hematologic responses were associated with a cardiac response and NT-proBNP reduction. After a median follow-up of 12 months, 29% of patients had organ progression and 27% had hematologic progression. Median survival has not been reached and the 1-year survival rate is 76%. Baseline NT-proBNP was independently associated with survival (P = .001), while in a landmark analysis, survival was associated with NT-proBNP reduction of ≥ 30% (P = .006) and achievement of hematologic response (P = .001). Toxicity was manageable and mostly consisted of neuropathy, orthostasis, peripheral edema, and constipation or diarrhea. Conclusion: Bortezomib with or without dexamethasone is active in AL amyloidosis and induces rapid responses and high rates of hematologic and organ responses. Serial measurement of cardiac biomarkers is a powerful predictor of outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Self-citationBortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationGertz, M. A., Comenzo, R., Falk, R. H., Fermand, J. P., Hazenberg, B. P., Hawkins, P. N., Merlini, G., Moreau, P., Ronco, P., Sanchorawala, V., et al. (2005) · American Journal of Hematology · doi:10.1002/ajh.20381 · Cited by 1,428
Self-citationDispenzieri, A., Gertz, M. A., Kyle, R. A., Lacy, M. Q., Burritt, M. F., Therneau, T. M., Greipp, P. R., Witzig, T. E., Lust, J. A., Rajkumar, S. V., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.029 · Cited by 985
Impaired Proteasome Function in Alzheimer's Disease
Keller, J. N., Hanni, K. B., & Markesbery, W. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750436.x · Cited by 848
Regulation of apoptosis by endoplasmic reticulum pathways
Breckenridge, D. G., Germain, M., Mathai, J. P., Nguyen, M., & Shore, G. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207108 · Cited by 740
Quality control in the endoplasmic reticulum protein factory
Sitia, R., & Braakman, I. (2003) · Nature · doi:10.1038/nature02262 · Cited by 688
Kyle, R. A., Gertz, M. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Lacy, M. Q., & Therneau, T. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361702 · Cited by 688
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., Recher, C., Asli, B., Lioure, B., Royer, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070484 · Cited by 519
Brenner, D. A., Jain, M., Pimentel, D. R., Wang, B., Connors, L. H., Skinner, M., Apstein, C. S., & Liao, R. (2004) · Circulation Research · doi:10.1161/01.res.0000126569.75419.74 · Cited by 450
Lachmann, H. J., Gallimore, R., Gillmore, J. D., Carr‐Smith, H. D., Bradwell, A. R., Pepys, M. B., & Hawkins, P. N. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04433.x · Cited by 435
Self-citationHarousseau, J., Attal, M., Leleu, X. P., Troncy, J., Pegourié, B., Stoppa, A., Hulin, C., Benboubker, L., Fuzibet, J., Renaud, M., et al. (2006) · PubMed · Cited by 367
Autologous stem cell transplantation for primary systemic amyloidosis
Comenzo, R. L., & Gertz, M. A. (2002) · Blood · doi:10.1182/blood.v99.12.4276 · Cited by 357
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins
Dispenzieri, A., Kyle, R. A., Gertz, M. A., Therneau, T. M., Miller, W. L., Chandrasekaran, K., McConnell, J. P., Burritt, M. F., & Jaffe, A. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13396-x · Cited by 317
Palladini, G., Lavatelli, F., Russo, P., Perlini, S., Perfetti, V., Bosoni, T., Obici, L., Bradwell, A. R., D'Eril, G. M., Fogari, R., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4385 · Cited by 311
Self-citationPomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
Sanchorawala, V., Shelton, A. C., Lo, S., Varga, C., Sloan, J. M., & Seldin, D. C. (2016) · Blood · doi:10.1182/blood-2016-04-710822 · Cited by 275
Dispenzieri, A., Lacy, M. Q., Zeldenrust, S. R., Hayman, S. R., Kumar, S. K., Geyer, S. M., Lust, J. A., Allred, J. B., Witzig, T. E., Rajkumar, S. V., et al. (2007) · Blood · doi:10.1182/blood-2006-07-032987 · Cited by 273
Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172734 · Cited by 267
Self-citationLenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S., Zeldis, J. B., Skinner, M., & Seldin, D. C. (2007) · Blood · doi:10.1182/blood-2006-07-030544 · Cited by 260
Chanan-Khan, A. A., Kaufman, J. L., Mehta, J., Richardson, P. G., Miller, K. C., Lonial, S., Munshi, N. C., Schlossman, R., Tariman, J., & Singhal, S. (2007) · Blood · doi:10.1182/blood-2006-09-046409 · Cited by 256
Wechalekar, A. D., Goodman, H. J. B., Lachmann, H. J., Offer, M., Hawkins, P. N., & Gillmore, J. D. (2007) · Blood · doi:10.1182/blood-2006-07-035352 · Cited by 233
Self-citationAnalysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables
Anderson, J. R., Cain, K. C., & Gelber, R. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1000 · Cited by 228
Palladini, G., Perfetti, V., Perlini, S., Obici, L., Lavatelli, F., Caccialanza, R., Invernizzi, R., Comotti, B., & Merlini, G. (2005) · Blood · doi:10.1182/blood-2004-08-3231 · Cited by 227
Self-citationSanchorawala, V., Skinner, M., Quillen, K., Finn, K. T., Doros, G., & Seldin, D. C. (2007) · Blood · doi:10.1182/blood-2007-07-099481 · Cited by 166
Casas, S., Gomis, R., Gribble, F. M., Altirriba, J., Knuutila, S., & Novials, A. (2007) · Diabetes · doi:10.2337/db07-0178 · Cited by 158
Huang, C.-J., Haataja, L., Gurlo, T., Butler, A. E., Wu, X., Soeller, W. C., & Butler, P. C. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00318.2007 · Cited by 149
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
Dispenzieri, A. A., Lacy, M. Q., Rajkumar, S. V., Geyer, S. M., Witzig, T. E., Fonseca, R., Lust, J. A., Greipp, P. R., Kyle, R. A., & Gertz, M. A. (2003) · Amyloid · doi:10.3109/13506120309041743 · Cited by 140
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Sitia, R., Palladini, G. O., & Merlini, G. (2007) · Haematologica · doi:10.3324/haematol.12136 · Cited by 95
Self-citationAmyloidosis and Waldenstrom’s Macroglobulinemia
Gertz, M. A., Merlini, G., & Treon, S. P. (2004) · Hematology · doi:10.1182/asheducation-2004.1.257 · Cited by 94
Self-citationEndoplasmic Reticulum Stress Associated with Extracellular Aggregates
Teixeira, P. F., Cerca, F., Santos, S. D., & Saraiva, M. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602302200 · Cited by 88
Ρούσσου, Μ., Kastritis, E., Migkou, M., Psimenou, E., Grapsa, I., Matsouka, C., Barmparousi, D., Terpos, E., & Dimopoulos, M. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801930506 · Cited by 82
Self-citationTherapy for immunoglobulin light chain amyloidosis: the new and the old
Gertz, M. A., Lacy, M. Q., & Dispenzieri, A. A. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00027-4 · Cited by 60
Cited by
Kumar, S., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Colby, C., Laumann, K., Zeldenrust, S. R., Leung, N., Dingli, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.5724 · Cited by 1,137
Wechalekar, A. D., Gillmore, J. D., & Hawkins, P. N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01274-x · Cited by 994
Self-citationAmyloidosis: Pathogenesis and New Therapeutic Options
Merlini, G., Seldin, D. C., & Gertz, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2271 · Cited by 509
Self-citationPalladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., Basset, M., Hawkins, P., Merlini, G., & Wechalekar, A. D. (2015) · Blood · doi:10.1182/blood-2015-01-620302 · Cited by 450
Self-citationTargeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Metadata
- Authors
- Kastritis, E., Wechalekar, A. D., Dimopoulos, M. A., Merlini, G., Hawkins, P. N., Perfetti, V., Gillmore, J. D., & Palladini, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-02-20
- Volume
- 28
- Issue
- 6
- Pages
- 1031-1037
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161231801
- Cited by
- 298
- References
- 34
- FWCI
- 11.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.